Multi-stage biodegradable drug delivery platform

Patent metadata

Field	Value
Publication number	US-10071199-B2
Application number	US-201414218409-A
Country	US
Kind code	B2
Filing date	Mar 18, 2014
Priority date	Mar 15, 2013
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

First claim

The invention claimed is:

1. A multi-stage biodegradable drug delivery platform, the platform comprising:
a body comprising a first biodegradable material, the body including a skin penetrating pointed end, the body and skin penetrating pointed end configured to allow the body to penetrate the skin of a mammal and be lodged in subcutaneous tissue by the application of a mechanical force on the body applied by a user's fingers, the body being at least partially hollow to define a primary cavity;
a shell defining a secondary cavity, the shell disposed within the body and comprising a second biodegradable material;
a first therapeutic agent dosage carried by the body in the primary cavity and disposed outside the shell, wherein the body has a first wall thickness configured to biodegrade in vivo over a first time period to then release the first therapeutic agent dosage within the mammal, and
a second therapeutic agent dosage disposed within the secondary cavity of the shell, wherein the shell is configured to biodegrade in vivo after a second time period, so as to release the second therapeutic agent dosage within the mammal after the first therapeutic dosage, wherein the shell has a wall thickness of about 1 to about 20 thousandths of an inch, and wherein the shell has a weight of about 90 mg to about 150 mg.

2. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the first and second therapeutic agent dosages comprise vaccine dosages and the first dosage is released before the second dosage.

3. The multi-stage biodegradable drug delivery platform of claim 2 , wherein the second dosage of vaccine is a booster dose and the second biomaterial comprises magnesium or a magnesium alloy that is configured to biodegrade to release the booster dose after a period of time in which the mammal's immunity to an antigen from the first dosage has decreased.

4. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the first biodegradable material comprises maltose and the first therapeutic agent dosage is released before the second dosage.

5. The multi-stage biodegradable drug delivery platform of claim 1 , the second biodegradable material comprises magnesium or a magnesium alloy and the second therapeutic agent dosage is released after the first dosage.

6. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the shell has a wall thickness of about 1 to about 10 thousandths of an inch.

7. The multi-stage biodegradable drug delivery platform of claim 6 , wherein the shell has a wall thickness of about 1 to about 5 thousandths of an inch.

8. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the shell has a wall thickness configured to biodegrade in vivo so as to release the second dosage from about 10 days to about 1 year after release of the first therapeutic agent dosage.

9. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the shell has a wall thickness configured to biodegrade in vivo in a period from about three months to about six months.

10. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the shell has a wall thickness of configured to biodegrade in vivo in about nine months.

11. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the first therapeutic agent dosage and the second therapeutic agent dosage comprise different therapeutic agents.

12. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the first therapeutic agent dosage and the second therapeutic agent dosage comprise at least one common therapeutic agent.

13. The multi-stage biodegradable drug delivery platform of claim 12 , wherein the first therapeutic agent dosage and the second therapeutic have different concentrations.

14. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the shell further comprises a tertiary cavity, separate and distinct from the secondary cavity, the tertiary cavity containing a third therapeutic agent dosage.

15. The multi-stage biodegradable drug delivery platform of claim 1 , wherein the second therapeutic agent dosage is a booster dose of therapeutic agent.

16. A multi-stage biodegradable drug delivery platform of claim 1 , wherein the first biodegradable material and the second biodegradable material have different rates of in vivo biodegradation.

17. A multi-stage biodegradable drug delivery platform, the platform comprising:
a body comprising a first biodegradable material, the body including a skin penetrating pointed end, the body and skin penetrating pointed end configured to allow the body to penetrate the skin of a mammal and be lodged in subcutaneous tissue by the application of a mechanical force on the body applied by a user's fingers at an end of the body opposite to the skin penetrating pointed end, the body being at least partially hollow to define a primary cavity;
a shell defining a secondary cavity, the shell disposed within the body and comprising a second biodegradable material, the secondary cavity having a first wall thickness of from about 1 to about 10 thousandths of an inch, further wherein the shell comprises a magnesium alloy comprising magnesium and at least one of zinc, manganese, aluminum, calcium, lithium, zirconium, or yttrium, and wherein the shell has a weight of about 93 mg to about 141 mg;
a first therapeutic agent dosage carried by the body in the primary cavity and disposed outside the shell so as to be releasable within the mammal by in vivo biodegradation of the body after a first time period; and
a second therapeutic agent dosage disposed within the secondary cavity of the shell so as to be releasable within the mammal by in vivo biodegradation of the shell after a second time period subsequent to release of the first dosage.

18. The multi-stage biodegradable drug delivery platform of claim 17 , wherein the first and second dosages of therapeutic agent are dosages of vaccine.

19. The multi-stage biodegradable drug delivery platform of claim 17 , wherein the first biodegradable material biodegrades at a faster rate in vivo than the second biodegradable material.

20. The multi-stage biodegradable drug delivery platform of claim 19 , wherein the first time period is substantially shorter than the second time period.

21. The multi-stage biodegradable drug delivery platform of claim 20 , wherein the first time period is up to about 20 minutes and the second time period is in a range of about one month to about twelve months.

22. The multi-stage biodegradable drug delivery platform of claim 19 , wherein the first biodegradable material is comprised of maltose.

23. The multi-stage biodegradable drug delivery platform of claim 17 , wherein the second time period is controlled by selection of a wall thickness of the shell and a rate of biodegradation of the magnesium alloy in vivo.

24. The multi-stage biodegradable drug delivery platform of claim 23 wherein the shell wall thickness and shell material are configured to biodegrade in vivo to release the second therapeutic agent dosage in about three months.

25. The multi-stage biodegradable drug delivery platform of claim 23 , wherein the shell wall thickness and shell material are configured to biodegrade in vivo to release the second therapeutic agent dosage in about six months.

26. The multi-stage biodegradable drug delivery platform of cl

Assignees

• Incube Labs Llc

Inventors

• Imran Mir

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/20

  for DNA viruses · CPC title